Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'Malcolm in the Middle' reboot releases 1st trailer, reuniting Frankie Muniz and Bryan Cranston: Watch here - 2Yes, NASA's launching Artemis 2 astronauts to the moon on April Fools' Day. It's not a joke.
- 34 DSLR Cameras for Amateurs in 2024
- 4‘Aid for Ukraine’ pierogi fundraiser event
- 5Boats escort freed whale away from shallow waters off German coast
- SpaceX's 1st 'Version 3' Super Heavy Starship booster buckles under pressure during initial tests
- 'Sex and the City' star Kim Cattrall marries longtime partner Russell Thomas in intimate London wedding
- Philippines evacuates 3,000 villagers after volcano activity raises alert level
- 7 Espresso Machines for Home Baristas
- 5 things for parents to know about changes to kids vaccine schedule
- Vote in favor of Your #1 sort of pie
- What you need to know about desalination, a growing source of drinking water
- Find the Mysteries of Effective Objective Setting: Transforming Dreams into Feasible Targets
- Between 600 to 800 aid trucks entering Gaza daily since start of ceasefire, COGAT confirms
